0000950170-25-103192 Sample Contracts

CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO FUNDING AGREEMENT
Funding Agreement • August 5th, 2025 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • New York

This FIRST AMENDMENT TO FUNDING AGREEMENT (this “Amendment”), dated as of June 27, 2025 is made and entered into by and among (i) HEDGEWIG FUNDING I LP, a Cayman Islands exempted limited partnership formed under the laws of the Cayman Islands (as successor to LSI Financing Fund, LP, a Cayman exempted limited partnership formed under the laws of the Cayman Islands (as successor to LSI Financing 1 Designated Activity Company, a designated activity company limited by shares duly incorporated under the laws of Ireland)), and CPPIB CREDIT EUROPE S.À R.L., a private limited liability company (société à responsabilité limitée) incorporated and organized under the Laws of the Grand Duchy of Luxembourg, as purchasers (each in such capacity, together with its permitted successors and assigns in such capacity, a “Purchaser” and collectively, the “Purchasers”), (ii) BRIDGEBIO PHARMA, INC., a Delaware corporation (“BridgeBio”) (iii) EIDOS THERAPEUTICS, INC., a Delaware corporation (“Eidos”), (iv) B

View Source
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ROYALTY INTEREST PURCHASE AND SALE AGREEMENT by and...
Royalty Interest Purchase and Sale Agreement • August 5th, 2025 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • New York

This ROYALTY INTEREST PURCHASE AND SALE AGREEMENT (this “Agreement”) dated as of June 27, 2025 (the “Effective Date”) is by and among EIDOS THERAPEUTICS, INC., a Delaware corporation (the “Company”) and BRIDGEBIO PHARMA, INC., a Delaware corporation (the “Parent”), on the one hand, and ACORAMIDIS ROYALTY SPV, LP, a Delaware limited partnership (“ARS”) and LSI FINANCING FUND, LP, a Cayman Islands exempted limited partnership formed under the laws of the Cayman Islands (“LSI”, and collectively with ARS, the “Purchasers”), and solely in its capacity as agent for, and representative of, the Purchasers, ACORAMIDIS ROYALTY SPV, LP (the “Purchaser Representative”), on the other hand. Each of the Company and the Purchasers are referred to in this Agreement as a “Party” and collectively as the “Parties”.

View Source